NAV

(S)-2-((S)-3-isobutyl-2,5-dioxo-4-quinolin-3-ylmethyl-[1,4]diazepan-1yl)-N-methyl-3-naphtalen-2-yl-propionamide

Identification

Generic Name
(S)-2-((S)-3-isobutyl-2,5-dioxo-4-quinolin-3-ylmethyl-[1,4]diazepan-1yl)-N-methyl-3-naphtalen-2-yl-propionamide
DrugBank Accession Number
DB04724
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
3D
Similar Structures
Weight
Average: 536.6639
Monoisotopic: 536.278741038
Chemical Formula
C33H36N4O3
Synonyms
Not Available
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UIntegrin alpha-LNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as quinolines and derivatives. These are compounds containing a quinoline moiety, which consists of a benzene ring fused to a pyrimidine ring to form benzo[b]azabenzene.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Not Available
Direct Parent
Quinolines and derivatives
Alternative Parents
Naphthalenes / Alpha amino acids and derivatives / 1,4-diazepanes / Pyridines and derivatives / Fatty amides / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Lactams / Azacyclic compounds
show 4 more
Substituents
1,4-diazepane / Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Diazepane / Fatty acyl
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinolines, monocarboxylic acid amide, naphthalenes, diazepanone (CHEBI:43574)
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
COVPLULNDBDXTN-KYJUHHDHSA-N
InChI
InChI=1S/C33H36N4O3/c1-22(2)16-30-33(40)36(29(32(39)34-3)19-23-12-13-25-8-4-5-9-26(25)17-23)15-14-31(38)37(30)21-24-18-27-10-6-7-11-28(27)35-20-24/h4-13,17-18,20,22,29-30H,14-16,19,21H2,1-3H3,(H,34,39)/t29-,30-/m0/s1
IUPAC Name
(2S)-N-methyl-2-[(3S)-3-(2-methylpropyl)-2,5-dioxo-4-[(quinolin-3-yl)methyl]-1,4-diazepan-1-yl]-3-(naphthalen-2-yl)propanamide
SMILES
CNC(=O)[C@H](CC1=CC2=CC=CC=C2C=C1)N1CCC(=O)N(CC2=CC3=CC=CC=C3N=C2)[C@@H](CC(C)C)C1=O

References

General References
Not Available
PubChem Compound
5326914
PubChem Substance
46505747
ChemSpider
4484198
BindingDB
50161067
ChEMBL
CHEMBL446435
ZINC
ZINC000016051670
PDBe Ligand
LA1
PDB Entries
1xuo

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00137 mg/mLALOGPS
logP4.09ALOGPS
logP4.29Chemaxon
logS-5.6ALOGPS
pKa (Strongest Acidic)15.64Chemaxon
pKa (Strongest Basic)4.18Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area82.61 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity155.17 m3·mol-1Chemaxon
Polarizability60.17 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9201
Blood Brain Barrier-0.6488
Caco-2 permeable-0.5881
P-glycoprotein substrateSubstrate0.9117
P-glycoprotein inhibitor IInhibitor0.9707
P-glycoprotein inhibitor IIInhibitor0.6791
Renal organic cation transporterNon-inhibitor0.6466
CYP450 2C9 substrateNon-substrate0.8282
CYP450 2D6 substrateNon-substrate0.7505
CYP450 3A4 substrateSubstrate0.8099
CYP450 1A2 substrateNon-inhibitor0.6613
CYP450 2C9 inhibitorNon-inhibitor0.5606
CYP450 2D6 inhibitorNon-inhibitor0.8803
CYP450 2C19 inhibitorNon-inhibitor0.5388
CYP450 3A4 inhibitorNon-inhibitor0.5103
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6748
Ames testNon AMES toxic0.6915
CarcinogenicityNon-carcinogens0.9379
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6660 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8971
hERG inhibition (predictor II)Inhibitor0.6501
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0100090000-e0b21ceb06b1b0793c31
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0k9f-9013080000-fe9e36806f946322b305
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0kdr-0914830000-ea4a522cfe533646ef2e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-6103290000-56d6294cac37554f5c9c
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0910100000-22277657a75ae2798779
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-053l-3915310000-4f68761c1c8e1084708b
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-229.63277
predicted
DeepCCS 1.0 (2019)
[M+H]+231.52818
predicted
DeepCCS 1.0 (2019)
[M+Na]+237.37523
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Integrin alpha-L
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Metal ion binding
Specific Function
Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated ...
Gene Name
ITGAL
Uniprot ID
P20701
Uniprot Name
Integrin alpha-L
Molecular Weight
128768.495 Da

Drug created at September 11, 2007 17:49 / Updated at June 12, 2020 16:52